Estimation the daily urinary excretion 131I radioactivity of thyroid cancer in patients with residual activity
Objective Through the determination of 131I posttreatment differentiated thyroid cancer patients' urine discharge 131I value in one day to estimate the residual 131I radioactivity in vivo, and combined with the national standard predict to forecast the patients' discharge time. Methods Measuring each of 35 differentiated thyroid cancer patient's urine radioactivity after take 131I, and calculating the total radioactivity in different time of each patient, and then estimating the total residual 131I radioactivity in patients. Results The 131I ablation therapy on remnant thyroid and 131I treatment on metastatic lesions in patients after the first day taking 131I, the urine discharge of radioactivity respectively was 2401.5MBq, 4144.5MBq(respectively accounts for 64.9% and 71% of the total taking 131I radioactivity), and the 131I ablation therapy on remnant thyroid and 131I treatment on metastatic lesions patients' residual 131I radioactivity in vivo respectively was 926.9MBq, 1081.1MBq(respectively accounts for 25.1% and 17.2% of total 131I radioactivity), followed by patients in the urine discharge of 131I radioactivity and the residual 131I radioactivity in vivo declines slowly. 20 cases of 131I ablation therapy on remnant thyroid and 15 cases of 131I treatment on metastatic lesions of patients, reach the national standard discharge time respectively was 3.1±2.2days and 1.9±1.1days. Conclusion The thyroid cancer patients who taking large doses of 131I will impact the surroundings and other people in a short term, so the patients must be hospitalized and isolated in the standard protective ward for average 2-3days(48-72h) before discharge.
Thyroid cancerRadioactive 131IMeasurement of 131I in urineResidual in vivo
NETL
NSTL
万方数据
维普
